Regeneron Pharmaceuticals

REGN

Market cap $69.1B

In the second quarter of 2026, the Baird Chautauqua International Growth Fund Net Investor Class returned +10.39%, underperforming the MSCI ACWI ex-U.S. Index® ND, which returned +14.49%. The largest relative detractors were Alibaba, Lululemon, and Brookfield Renewable, while the largest relative contributors were Recruit, ASML, and Keyence. The Baird Chautauqua Global Growth Fund Net Investor Class returned +12.18% during the quarter, underperforming the MSCI ACWI Index® ND, which returned +14.93%.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The U.S. ​Food and ‌Drug Administration has ​selected Eli ​Lilly and Regeneron , ⁠among ​seven companies, ​for a pilot program ​to ​accelerate reviews of ‌new ⁠domestic pharmaceutical manufacturing facilities, CNBC ​reported ​on ⁠Monday citing ​an ​FDA ⁠spokesperson.

Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.

Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.